Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13215732 | 0.85 | ALDH1A1 (0.57) | MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL9893059 | 0.85 | MAPK1 (0.56) | MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL9892993 | 0.84 | MAPK1 (0.55) | MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL3572935 | 0.84 | ALDH1A1 (0.60) | MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL24108929 | 0.84 | HDAC8 (0.44) | MAPK1ALDH1A1SPHK1SPHK2HDAC8 | |
| SCHEMBL1242026 | 0.84 | SPHK1 (0.60) | SPHK1SPHK2 | |
| SCHEMBL1239254 | 0.84 | SPHK1 (0.60) | SPHK1SPHK2 | |
| SCHEMBL1239249 | 0.84 | SPHK1 (0.60) | SPHK1SPHK2 | |
| SCHEMBL3563591 | 0.84 | HDAC8 (0.51) | MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL13343697 | 0.84 | HDAC8 (0.51) | MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | MAPK1 253/4885ALDH1A1 1303/4885CRHBP 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.